MedTrace Logo

Ruxolitinib for Cancer Cachexia

NCT04906746 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-07-28

No results posted yet for this study

Summary

To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.

Conditions

  • Stage IV Non-small Cell Lung Cancer
  • Cachexia

Interventions

DRUG

Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.

There will be intra-patient dose escalation of ruxolitinib in every patient enrolled on study.

Sponsors & Collaborators

Principal Investigators

  • Tu Dan, MD · UT Southwestern Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-23
Primary Completion
2024-09-27
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906746 on ClinicalTrials.gov